Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Mastocytosis, Systemic × sarilumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Triple Negative Breast Neoplasms 1 Pathologic Complete Response 1 Neoplasms 1 Melanoma 1 Mastocytosis, Systemic 1 Hemangiosarcoma 1 Carcinoma, Non-Small-Cell Lung 1 Breast Neoplasms 1

Interventions

midostaurin 2 avapritinib 2 sarilumab 1 obatoclax 1 ibrutinib 1 denileukin diftitox 1 Imatinib Mesylate 1 Everolimus 1 Dasatinib 1 Brentuximab Vedotin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03770273 2024-12-17

Safety and Efficacy of Subcutaneous Sarilumab in Improving the Quality of Life in People With Indolent Systemic Mastocytosis

National Institutes of Health Clinical Center (CC)

Phase 2 Completed

21 enrolled 13 charts

Mastocytosis, Systemic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡